Molecular targeted therapy in acute myeloid leukemia

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Daver, Naval ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; FLT3 protein; JAK2; RAS

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZ 960; AZACITIDINE; CD135 ANTIGEN; CYT 387; CYTARABINE; FLT3 LIGAND; IDARUBICIN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; KI 11502; KW 2449; LESTAURTINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MSC 1936369B; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLERIXAFOR; PROTEIN KINASE TYK2; QUIZARTINIB; RAS PROTEIN; RUXOLITINIB; SB 1518; SELUMETINIB; SORAFENIB; SUNITINIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BLURRED VISION; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DIARRHEA; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HEART EJECTION FRACTION; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; OPTIC NERVE DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BENZOTHIAZOLES; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MUTATION; PHENYLUREA COMPOUNDS; PYRIDINES; RAS PROTEINS; STAUROSPORINE;

EID: 84859768494     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155619     Document Type: Review

References (21)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
2. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med. 2003;349(8):727-9.
3. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431-48.
4. + lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005; 121(2):295-306.
5. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-35.
6. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, http://www.ncbi.nlm.nih.gov/pubmed?term5 %22Carroll%20AJ%22%5BAuthor%5D et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233-9.
7. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92.
8. Cortes J, Foran J, Ghirdaladze D, DeVetten MP, Zodelava M, Holman P, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) Inhibitor, in a first-inhuman (FIH) phase 1 AML study. Blood. 2009;114(22):264.
9. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184-98.
10. Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma. 2010;51(2):252-60.
11. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567-71.
12. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856-62.
13. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multitargeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339-45.
14. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005;11(21):2779-95.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
16. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/ Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14(2):342-6.
17. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11(12):1192-7.
18. Falchook G, Infante JR, Fecher LA, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. The oral Mek 1/2 inhibitor Gsk1120212 demonstrates early efficacy signals. Ann Oncol. 2010;21:162.
19. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
20. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006; 20(6):971-8.
21. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivins C. Significant activity of the JAK2 inhibitor, INCB018424 in patients with secondary, post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML): results of an exploratory phase II study. Blood. 2009;114(22):261-2.